Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine in Newly-Diagnosed DIPG
NCT02992015Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Sep 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine in diffuse intrinsic pontine glioma (DIPG), sponsored by University of Colorado Denver. Primary endpoint: Gemcitabine and metabolite concentrations in blood and tissue. Started Sep 2016; status: completed.
02
Drugs
gemcitabine
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT02992015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992015.